AS1411: Phase II started

Antisoma began an open-label, U.S. Phase II trial to evaluate 40 mg/kg/day of IV AS1411 as monotherapy in 30 patients intolerant to, or relapsed after, therapy with Sutent sunitinib or Nexavar soraf...